ClinicaliQ Trial Snapshot
- A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection — Active Not Recruiting • Phase III • Oncology • NCT05120349.
- Osimertinib after surgery improves survival in early-stage lung cancer patients with specific EGFR mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection. Conditions: Non-Small Cell Lung Cancer Interventions: Osimertinib, Placebo Lead Sponsor: AstraZeneca Planned Enrollment: 390 participants